Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds

Details Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds

2011-05-31

2011-05-31

Aulakh, Charanjit S (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S020000

Reexamination Certificate

active

07951815

ABSTRACT:
Novel 1,4,8-triazaspiro[4,5]decan-2-one compounds corresponding to formula Iprocesses for the preparation thereof, related methods of treatment and pharmaceutical formulations containing such compounds.

REFERENCES:
patent: 3725389 (1973-04-01), McCaully et al.
patent: 0 921 125 (1999-06-01), None
patent: 0 963 985 (2001-01-01), None
patent: 01207291 (1989-08-01), None
Hendershot, L.C. et al., “Antagonism of the Frequency of Phenylquinone-Induced Writhing in the Mouse by Weak Analgesics and Nonanalgesics”, J. Pharmacol. Exp. Ther. 125, Sep. 19, 1958, pp. 237-240, The Biochemical Research Laboratory, The Dow Chemical Company, Midland, Michigan.
Frink, Martin CH. et al., “Influence of Tramadol on Neurotransmitter Systems of the Rat Brain”, Arzneim-Forsch./Drug Res. 46 (II), Nr. 11, pp. 1029-1036 (1996).
Cheng, Yung-Chi et al., “Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I50) of an Enzymatic Reaction”, Biochemical Pharmacology, vol. 22, pp. 3099-3108, Pergamon Press, 1973, Great Britain.
“Remington's Pharmaceutical Sciences”, Editor A.R. Gennaro, 17thEdition, Mack Publishing Company 1985, Chapters 76 to 93, particularly Section 8, provided herewith is the Table of Contents.
Gray, E.G. et al., “The Isolation of Nerve Endings From Brain: An Electron-Microscopic Study of Cell Fragments Derived by Homogenization and Centrifugation”, Journal of Anatomy, vol. 96, Part 1, 1962, pp. 79-88.
Pauwels, Petrus et al., “[3H]Batrachotoxinin A 20-α-Benzoate Binding to Sodium Channels in Rat Brain: Characterization and Pharmacological Significance”, European Journal of Pharmacology, 124 (1986) pp. 291-298.
Lowry, Oliver H. et al., “Protein Measurement With the Folin Phenol Reagent”, J. Biol. Chem., 193, pp. 265-275, 1951, Department of Pharmacology, Washington University School of Medicine, St. Louis, Missouri.
Lidia et al.,Journal of Combinatorial Chemistry(2003), 5(4).S.356-361, Chemical Abstracts, STN(HCAPLUS), Accession No. (AN):2003-323987; Abstr.
“Acyl . . . ”, http://www.roempp.com/prod/roempp.php, Oct. 21, 2004.
Anger et al., Medicinal Chemistry of Neuronal Voltage-Gated Sodium Channel Blockers,Journal of Medicinal Chemistry, vol. 44, No. 2, pp. 115-137. Jan. 18, 2001.
Madge, David J., Sodium Channels: Recent Developments and Therapeutic Potential,Annual Reports in Medicinal Chemistry, Chapter 6., pp. 51-60. 1998.
Nielsen et al., Sertraline, a serotonin-uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice,The American Journal of Clinical Nutrition, 1992; 55: 185S-8S.
Pires et al., Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice,Brazilian Journal of Medical and Biological Research, 2005; 38: 1867-1872.
Rausch et al., Fluvoxamine treatment of mixed anxiety and depression: evidence for serotonergically mediated anxiolysis,Journal of Clinical Psychopharmacology, 2001; 21(2); 139-42. Abstract only.
Sacre et al., Fluxetine and citalopram exhibit potent anti-inflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors,Arthritis&Rheumatism, published online Jan. 7, 2010.
Sumpton et al., Treatment of neuropathic pain with venlafaxine,The Annals of Pharmacotherapy, 2001; vol. 35, No. 5, pp. 557-559. Abstract only.
Sweetnam et al., Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity,Psychopharmacology, 1995; 118: 269-376.

Affiliated with

Also associated with

Rating

Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2666358